Literature DB >> 25008999

MGMT gene silencing by promoter hypermethylation in gastric cancer in a high incidence area.

Adfar Yousuf1, Mohammad Younis Bhat, Arshad A Pandith, Dil Afroze, Nighat P Khan, Khursheed Alam, Parveen Shah, M Amin Shah, Syed Mudassar.   

Abstract

PURPOSE: Inactivation of tumor suppressor and DNA repair genes by promoter hypermethylation does commonly occur in human cancers. O(6)-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme that removes methyl groups as well as larger adducts at the O(6) position of guanine. In the absence of MGMT activity, O(6)-methylguanine mispairs with thymine during DNA replication, resulting in G:C to A:T transitions. Promoter hypermethylation of the MGMT gene has been observed in various cancers, including gastric cancer. Here, we aimed at assessing the promoter hypermethylation, mutation and expression status of the MGMT gene in patients from a geographic region with a high incidence of gastric cancer (Kashmir, North India) and to investigate their association with various clinicopathological characteristics.
METHODS: In this study 82 gastric cancer samples and adjacent normal tissues were included. Mutations in the MGMT gene were detected by single stranded conformational polymorphism (SSCP) analysis and direct sequencing. Methylation-specific polymerase chain reaction (MS-PCR) and Western blot analyses were performed to detect promoter hypermethylation and concomitant (loss of) expression of the MGMT gene.
RESULTS: Promoter hypermethylation of the MGMT gene was found in 52.44% (43 of 82) of the tumor samples and loss of MGMT protein expression was detected in 45.12% (37 of 82) of the tumor samples. Hypermethylation and loss of expression were significantly associated with higher tumor grades (moderately/poorly differentiated) (P < 0.05) and higher tumor stages (III/IV) (P < 0.05). In addition, MGMT hypermethylation and loss of expression were found to be significantly associated with high salt tea consumption (P < 0.05).
CONCLUSIONS: Our results indicate that MGMT promoter hypermethylation and concomitant loss of MGMT protein expression may play an important role in the development of gastric cancer in the Kashmiri population. High salt tea consumption may be a risk factor.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25008999     DOI: 10.1007/s13402-014-0179-3

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  42 in total

1.  MGMT promoter methylation and field defect in sporadic colorectal cancer.

Authors:  Lanlan Shen; Yutaka Kondo; Gary L Rosner; Lianchun Xiao; Natalie Supunpong Hernandez; Jill Vilaythong; P Scott Houlihan; Robert S Krouse; Anil R Prasad; Janine G Einspahr; Julie Buckmeier; David S Alberts; Stanley R Hamilton; Jean-Pierre J Issa
Journal:  J Natl Cancer Inst       Date:  2005-09-21       Impact factor: 13.506

2.  Impaired expression and promotor hypermethylation of O6-methylguanine-DNA methyltransferase in retinoblastoma tissues.

Authors:  Kwong Wai Choy; Chi Pui Pang; Ka Fai To; Christopher B O Yu; Joan S K Ng; Dennis S C Lam
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-05       Impact factor: 4.799

3.  Promoter hypermethylation of MGMT is associated with protein loss in gastric carcinoma.

Authors:  N Oue; H Shigeishi; H Kuniyasu; H Yokozaki; K Kuraoka; R Ito; W Yasui
Journal:  Int J Cancer       Date:  2001-09       Impact factor: 7.396

4.  Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients.

Authors:  Yang Liu; Qing Lan; Jill M Siegfried; James D Luketich; Phouthone Keohavong
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

5.  Caffeine-derived N-nitroso compounds--I: Nitrosatable precursors from caffeine and their potential relevance in the etiology of oesophageal and gastric cancers in Kashmir, India.

Authors:  R Kumar; P Mende; C D Wacker; B Spiegelhalder; R Preussmann; M Siddiqi
Journal:  Carcinogenesis       Date:  1992-11       Impact factor: 4.944

6.  Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.

Authors:  Xiao-Ping Zou; Bin Zhang; Xiao-Qi Zhang; Min Chen; Jun Cao; Wen-Jia Liu
Journal:  Hum Pathol       Date:  2009-08-19       Impact factor: 3.466

7.  Estimate of cancer incidence in India in 1991.

Authors:  D N Rao; B Ganesh
Journal:  Indian J Cancer       Date:  1998-03       Impact factor: 1.224

8.  Profile of aberrant CpG island methylation along multistep gastric carcinogenesis.

Authors:  Gyeong Hoon Kang; Sun Lee; Jung-Sun Kim; Hwoon-Yong Jung
Journal:  Lab Invest       Date:  2003-04       Impact factor: 5.662

9.  Methylation of the MGMT gene is frequently detected in advanced gastric carcinoma.

Authors:  Kenji Hibi; Makiko Sakata; Kazuaki Yokomizo; Yo-Hei Kitamura; Kazuma Sakuraba; Atsushi Shirahata; Tetsuhiro Goto; Hiroki Mizukami; Mitsuo Saito; Kazuyoshi Ishibashi; Gaku Kigawa; Hiroshi Nemoto; Yutaka Sanada
Journal:  Anticancer Res       Date:  2009-12       Impact factor: 2.480

10.  Localization of methylation sites in the human O6-methylguanine-DNA methyltransferase promoter: correlation with gene suppression.

Authors:  X Qian; M A von Wronski; T P Brent
Journal:  Carcinogenesis       Date:  1995-06       Impact factor: 4.944

View more
  20 in total

1.  Associations between polymorphisms in the SYK promoter and susceptibility to sporadic colorectal cancer in a Southern Han Chinese population - a short report.

Authors:  Hui Peng; Jun Huang; Ying Hu; Yisheng Wei; Huanliang Liu; Meijin Huang; Lei Wang; Jianping Wang
Journal:  Cell Oncol (Dordr)       Date:  2015-04-29       Impact factor: 6.730

2.  DNA methylation patterns in EBV-positive and EBV-negative Hodgkin lymphomas.

Authors:  Myriam Ben Dhiab; Sonia Ziadi; Sarra Mestiri; Riadh Ben Gacem; Feryel Ksiaa; Mounir Trimeche
Journal:  Cell Oncol (Dordr)       Date:  2015-09-08       Impact factor: 6.730

3.  MGMT DNA repair gene promoter/enhancer haplotypes alter transcription factor binding and gene expression.

Authors:  Meixiang Xu; Courtney E Cross; Jordan T Speidel; Sherif Z Abdel-Rahman
Journal:  Cell Oncol (Dordr)       Date:  2016-06-15       Impact factor: 6.730

4.  Melanoma associated antigen (MAGE)-A3 promotes cell proliferation and chemotherapeutic drug resistance in gastric cancer.

Authors:  Chen Xie; Vinod Vijay Subhash; Arpita Datta; Natalia Liem; Shi Hui Tan; Mei Shi Yeo; Woei Loon Tan; Vivien Koh; Fui Leng Yan; Foong Ying Wong; Wai Keong Wong; Jimmy So; Iain Beehuat Tan; Nisha Padmanabhan; Celestial T Yap; Patrick Tan; Liang Kee Goh; Wei Peng Yong
Journal:  Cell Oncol (Dordr)       Date:  2016-02-11       Impact factor: 6.730

5.  Aberrant SOX11 promoter methylation is associated with poor prognosis in gastric cancer.

Authors:  Xiaoyang Xu; Xiaojing Chang; Zhenhua Li; Jiang Wang; Peng Deng; Xinjiang Zhu; Jian Liu; Chundong Zhang; Shuchen Chen; Dongqiu Dai
Journal:  Cell Oncol (Dordr)       Date:  2015-03-24       Impact factor: 6.730

Review 6.  Consensus reference gene(s) for gene expression studies in human cancers: end of the tunnel visible?

Authors:  R N Sharan; S Thangminlal Vaiphei; Saibadaiahun Nongrum; Joshua Keppen; Mandahakani Ksoo
Journal:  Cell Oncol (Dordr)       Date:  2015-09-18       Impact factor: 6.730

7.  miR-221-3p promotes hepatocellular carcinogenesis by downregulating O6-methylguanine-DNA methyltransferase.

Authors:  Zushun Chen; Bangde Xiang; Lunan Qi; Shaoliang Zhu; Lequn Li
Journal:  Cancer Biol Ther       Date:  2020-10-06       Impact factor: 4.742

8.  DBD-F induces apoptosis in gastric cancer-derived cells through suppressing HIF2α expression.

Authors:  Guang-Hui Tong; Wei-Wei Tong; Xiao-Song Qin; Li-Ping Lu; Yong Liu
Journal:  Cell Oncol (Dordr)       Date:  2015-11-02       Impact factor: 6.730

Review 9.  Challenges of deciphering gastric cancer heterogeneity.

Authors:  Petra Hudler
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

10.  miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway.

Authors:  Ismael Riquelme; Oscar Tapia; Pamela Leal; Alejandra Sandoval; Matthew G Varga; Pablo Letelier; Kurt Buchegger; Carolina Bizama; Jaime A Espinoza; Richard M Peek; Juan Carlos Araya; Juan Carlos Roa
Journal:  Cell Oncol (Dordr)       Date:  2015-10-12       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.